A call for advocacy and patient voice to eliminate hepatitis B virus infection
- PMID: 35278394
- DOI: 10.1016/S2468-1253(21)00475-1
A call for advocacy and patient voice to eliminate hepatitis B virus infection
Conflict of interest statement
CC declares independent grants for public health programming, outreach, and education from Gilead Sciences, VBI Vaccines, Dynavax Technologies, Arbutus Biopharma, Janssen Pharmaceuticals, GlaxoSmithKline (GSK), Bristol Myers Squibb, and Antios Therapeutics paid to the Hepatitis B Foundation; serves on advisory committees for Gilead Sciences and GSK; has received GSK support for attending meetings, including the American Association for the Study of Liver Diseases 2019; and has received honoraria for presentation for the Hepatitis B–Therapeutic Agents Meeting 2021. JVL has received grants and speaker fees from AbbVie, Gilead Sciences, and MSD, and speaker consultancy fees from AbbVie, Gilead Sciences, Intercept, Janssen Pharmaceuticals, MSD, Novo Nordisk, and GSK. AME has received personal consultancy fees and payments for lectures, presentations, and educational events from Gilead Sciences and GSK. PCM is funded by the Wellcome Trust (grant 110110/Z/ 15/Z) and receives a contribution to funding a PhD studentship from GSK. JC serves on a patient advisory committee for GSK. SW declares a research grant from Gilead Sciences paid to her institution; is a voluntary board member for World Hepatitis Alliance and the Hepatitis B Foundation; and has received payments or honoraria from CME Outfitters, FocusMed education, and Gilead Sciences. This work was supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (CC2223), the UK Medical Research Council (CC2223), and the Wellcome Trust (CC2223). This research was funded in whole, or in part, by the Wellcome Trust (CC2223).
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
